Sarepta Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $658,412 | $467,172 | $362,931 | $413,464 |
Gross Profit | 526,108 | 375,481 | 309,667 | 362,905 |
EBITDA | 186,673 | 48,730 | 12,030 | 58,310 |
EBIT | 176,218 | 38,924 | -701 | 45,614 |
Net Income | 159,049 | 33,611 | 6,460 | 36,119 |
Net Change In Cash | 658,412 | 467,172 | 362,931 | 413,464 |
Free Cash Flow | 53,964 | -97,962 | -14,225 | -284,520 |
Cash | 1,103,010 | 197,855 | 383,622 | 427,290 |
Basic Shares | 108,474 | 100,448 | 94,618 | 99,114 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,901,979 | $1,243,336 | $933,013 | $701,887 |
Gross Profit | 1,582,880 | 1,092,993 | 793,024 | 604,838 |
EBITDA | 316,889 | -439,196 | -582,116 | -306,081 |
EBIT | 279,165 | -498,088 | -636,715 | -355,423 |
Net Income | 235,239 | -535,977 | -703,488 | -418,780 |
Net Change In Cash | 1,901,979 | 1,243,336 | 933,013 | 701,887 |
Cost of Revenue | 613,810 | |||
Free Cash Flow | -342,743 | -588,338 | -356,170 | -481,662 |
Cash | 1,103,010 | 428,430 | 966,777 | 2,115,869 |
Basic Shares | 107,875 | 92,398 | 87,559 | 81,262 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $1.90 |
2024-09-30 | $0.34 |
2024-06-30 | $0.07 |
2024-03-31 | $0.37 |
